In this randomized, double-blind study, 126 mild to moderate essential hypertensive patients from northern China were studied to determine the efficacy and safety of a combination therapy of valsartan and hydrochlorothiazide. Patients were randomized to the V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide) group or the V80 (80 mg valsartan) group. Six weeks after treatment, the mean decrease from baseline in mean sitting systolic blood pressure (MSSBP) was significantly higher in the V80/H12.5 group than the V80 group, but there was no difference in the change of mean sitting diastolic blood pressure (MSDBP) in the two groups. Overall, 80.33% and 70.97% had a controlled response (normalized MSDBP), and 85.25% and 77.42% had a diastolic response (normalized MSDBP or > 10 mmHg reduction in MSDBP) in the V80/H12.5 and V80 groups, respectively (not significantly different). The incidence of adverse events was also similar between the two groups. The combination of 80 mg valsartan/12.5 mg hydrochlorothiazide was efficacious and well tolerated in mild and moderate essential hypertensive patients.
Introduction
Hypertension is a global public health challenge and is also becoming more prevalent in China. 1, 2 A survey in 1998 indicated that the prevalence of hypertension was 24.0% in people aged 35 -59 in China, and that only 19.9% of treated hypertensive patients achieved their blood pressure (BP) targets. 3 Poor treatment compliance and inadequate dosing were assumed to explain the unacceptably low control of blood pressure. 4, 5 Many clinical trials have indicated that the combination of two antihypertensive agents with different mechanisms of action can provide greater BP reduction, with no significant increase in Randomized, Double-blinded Trial Evaluation of Valsartan/ Hydrochlorothiazide Combination Therapy in Mild to Moderate Essential Hypertension in North-east China overall adverse events. 6 -8 Both European and American treatment guidelines also acknowledge that it is likely that combination drug therapy is needed to achieve BP targets. 9, 10 It is generally believed that BP, the prevalence of hypertension and the antihypertensive response may all be influenced by genetic factors as well as environmental factors, such as high sodium intake and cigarette smoking. 11 -13 Populations in northern China have a distinct genetic background and lifestyle compared with Americans and Europeans so, although, combination therapy has been shown to be a rational alternative to conventional monotherapy in the first-line treatment of hypertension for some patients in America and Europe, 14 a comparison of combination therapy with monotherapy on hypertensive patients in northern China is essential.
The combination of an angiotensin II receptor blocker (ARB) with a diuretic, hydrochlorothiazide (HCTZ), has been shown to be efficacious and well tolerated. 15, 16 The ARB inhibits angiotensin II-induced vasoconstriction and aldosteronemediated renal sodium retention, 17 and the HCTZ reduces intravascular volume. 18 Valsartan is a newly introduced ARB.
In the present study, therefore, valsartan and HCTZ combination therapy in patients from northern China with mild to moderate essential hypertension was compared with valsartan monotherapy.
Patients and methods
This study was an 8-week, multicentre, randomized, double-blind trial, which recruited patients from three centres in northern China (one in Jilin Province and two in Heilongjiang Province). Harbin Medical University Ethics Committee approved the study protocol prior to initiation and all study participants provided written informed consent before enrolment.
PATIENTS
Residents living in northern China with mild to moderate hypertension were recruited. Inclusion criteria included Chinese nationality, resident of northern China, age 20 -75 years, essential hypertension with a mean sitting diastolic blood pressure (MSDBP) ≥ 95 mmHg but < 110 mmHg, a mean sitting systolic blood pressure (MSSBP) < 180 mmHg, and body mass index (BMI) ≤ 30 kg/m 2 .
Patients with the following conditions were excluded: secondary hypertension, severe renal dysfunction, severe liver dysfunction, severe respiratory diseases, endocrine disorder, severe arrhythmia, heart failure, or if they were judged to be ineligible by a physician. Women who were pregnant, breast-feeding or of child-bearing age and not using an approved method of contraception were also excluded.
DRUG WASH-OUT PERIOD
All eligible patients underwent a 2-week drug wash-out period during which all medication thought to affect blood pressure was discontinued. After the drug wash-out period, patients with a MSDBP ≥ 95 mmHg but < 110 mmHg and a MSSBP < 180 mmHg were enrolled.
TREATMENT SCHEDULE
Patients were randomly assigned to receive either 80 mg valsartan (V80) or a fixed-dose combination of 80 mg valsartan and 12.5 mg HCTZ (V80/H12.5) orally daily for 6 weeks. They were followed up in the outpatient clinic every 2 weeks to check blood pressure changes, compliance and adverse events. The dose was doubled to 160 mg valsartan in the V80 group and to 160 mg S Zhang, B Yu, L Li et al. Valsartan/hydrochlorothiazide and essential hypertension valsartan and 25 mg HCTZ orally daily in the V80/H12.5 group if patients had a MSDBP > 90 mmHg after 4 weeks of treatment (visit 3) ( Fig. 1 ). Other antihypertensive drugs and any other drugs that might affect blood pressure were prohibited during the study period.
CLINICAL AND BIOCHEMICAL ASSESSMENT
During each visit, the MSSBP and MSDBP were measured in the morning and after the patient had rested in a sitting position for at least 10 min. The patients were also questioned about side-effects and compliance was monitored by counting the number of unused capsules returned. Routine urinalysis, haemanalysis and blood chemistry, including aspartate aminotransferase, alanine aminotransferase, urea nitrogen, creatinine, fasting glucose, total bilirubin and uric acid, cholesterol, triglyceride, low-density lipoprotein cholesterol, sodium, potassium and chloride, were performed before and after the study period. Serum potassium was also measured at 2 weeks (visit 2) and 4 weeks (visit 3) after the initiation of medication ( Fig. 1 ).
EFFICACY EVALUATION
Blood pressure changes after treatment were classified as a controlled response if MSDBP < 90 mmHg. Diastolic response was defined as a MSDBP < 90 mmHg or > 10 mmHg reduction from baseline.
STATISTICAL ANALYSES
Homogeneity in the demographic characteristics between the two groups of patients was examined using Student's t-test for continuous variables and the χ 2 -test for categorical variables. Changes in blood pressure and blood pressure after treatment in the two groups were compared using the Student's paired t-test and Student's t-test, respectively. Blood pressure control in the FIGURE 1: Treatment and assessment schedule. Patients with essential hypertension were randomized to receive 80 mg valsartan and 12.5 mg hydrochlorothiazide (V80/H12.5) or 80 mg valsartan (V80) daily for 6 weeks. V0, initial screening; V1, randomization; V2, 2 weeks' treatment; V3, 4 weeks' treatment; and V4, 6 weeks' treatment. MSDBP, mean sitting diastolic blood pressure; MSSBP, mean sitting systolic blood pressure; K + , serum potassium levels two groups was compared using the χ 2 -test. Serum potassium levels were compared using multivariate analysis of variance algorithms and the incidence of adverse events was analysed using Fisher's exact test. Data were presented as mean ± SD and a P-value < 0.05 was considered statistically significant.
Results

PATIENT CHARACTERISTICS
A total of 126 patients were randomized and entered the double-blind phase of this study. Three patients discontinued the study (two patients taking V80/H12.5 and one patient taking V80). The reasons for discontinuation were withdrawn consent and loss to followup in both groups; there was no significant difference in the expulsion rate between the two groups. The patients' demographic characteristics are summarized in Table 1 . No statistically significant differences were observed between the two groups with respect to gender, age, height, weight, BMI and history of hypertension. The baseline MSDBP and MSSBP were also similar between the two groups.
MEAN CHANGE IN BLOOD PRESSURE
The mean decreases in MSDBP and MSSBP from baseline after 6 weeks of treatment are shown in Table 2 . Compared with baseline, significant reductions in MSDBP and MSSBP were observed in both groups (P < 0.0001). There was no statistical difference between the groups with regard to the reduction in MSDBP, however the MSSBP in the V80/H12.5 group was significantly reduced, compared with the V80 group (P = 0.0108). Table 3 . Both of these results were not statistically significant between the two groups. In order to ensure the reliability of the result, an order logic model was used to adjust the centre for analysis. This showed that, although the diastolic response between the two treatment groups was close to significance (P < 0.0645) it did not actually reach significance (Table 4 ).
THERAPEUTIC RESPONSE
Since the drug dose was doubled if the MSDBP was > 90 mmHg 4 weeks after the start of treatment, the number of pills taken in the two groups was compared and found to be 41.97 ± 3.97 in the V80/H12.5 group and 42.92 ± 5.62 in the V80 group (not statistically significant). Overall, 18 and 21 patients in the V80/H12.5 group and the V80 group, respectively, had their dose doubled (not statistically significant). 
Reduction in MSDBP
SAFETY
The incidences of adverse events are summarized in Table 5 ; 13 (20.97%) patients in the V80/H12.5 group and 10 (15.63%) in the V80 group experienced one or more adverse events. There were no significant differences in the incidences of adverse events between the two groups. Headache, dizziness and chest distress were the most commonly reported drug-related adverse reactions. Furthermore, in the V80/H12.5 group, adverse events were experienced by six patients who had their dose doubled after 4 weeks of treatment (visit 3) compared with 12 patients who did not have their dose doubled. There was no significant difference in the incidence of adverse events between patients who had their dose doubled compared with those who did not, so doubling the dose had no effect on adverse events and adverse reactions.
Owing to the anti-mineralocorticoid effects of valsartan and the diuretic effects of hydrochlorothiazide, serum potassium levels were determined at baseline and after 2, 4 and 6 weeks of therapy and analysed by multivariate analysis of variance algorithms. The results showed that both monotherapy and combination therapy had no effect on serum potassium levels and there was no significant difference between the two groups ( Table 6 ).
Discussion
The present study randomized patients with mild to moderate hypertension in northern China to receive monotherapy with 80 mg valsartan or combination therapy with 80 The results showed that, compared with baseline, both MSSBP and MSDBP significantly decreased in the two groups, however the decrease in MSSBP, but not MSDBP, was significantly greater in the V80/H12.5 group than the V80 group. This finding has particular clinical relevance because the control of SBP is more difficult than the control of DBP and the reduction in SBP, especially in patients > 50 years of age, is directly correlated with a reduction in the risk for cardiovascular mortality. 7, 10, 19, 20 It can, therefore, be concluded that for patients with mild to moderate hypertension in northern China, combination therapy with valsartan and HCTZ is associated with a greater reduction in SBP and greater clinical significance, and can be used as an alternative to monotherapy in the first-line treatment of hypertension.
Previous studies have shown that the combination of valsartan and HCTZ can significantly decrease blood pressure. 6, 7, 15 Recently, Pool et al. 7 demonstrated that combination therapy with 160 mg valsartan and 12.5 mg HCTZ was associated with significantly greater reductions in blood pressure than monotherapies and a placebo in a multicentre study of hypertensive patients from the USA and Canada. Previous studies have shown that the antihypertensive effect can be influenced by genetic and environmental factors. 21, 22 We suggest, therefore, that the difference in the effective antihypertensive dosages between our present study and that reported by Pool et al. 7 is probably the result of different lifestyles, build and genotype between the enrolled patients. Furthermore, the current study also showed that it was efficacious and safe to double the dose of antihypertensive drugs for patients with a MSDBP > 90 mmHg after 4 weeks of treatment.
The adverse events of antihypertensive drugs are important factors in influencing treatment compliance. Combination treatment can decrease drug-related adverse events. Valsartan has been found to inhibit the production of aldosterone, resulting in hyperkalaemia; however, HCTZ-induced potassium loss can avoid the occurrence of valsartan-induced hyperkalaemia. 6, 7 In the current study, serum potassium levels were normal in both groups during treatment. In addition, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC- 7) has advised that much attention should be paid to hypotension if combination therapy is initiated. 10 The present study showed that the incidence of drug-related adverse events (transient headache, dizziness and chest distress) was similar in the two groups and, in this study, no patients discontinued the study due to adverse effects.
In conclusion, low-dosage combination therapy with 80 mg valsartan and 12.5 mg HCTZ daily as an initial treatment for patients with mild to moderate hypertension in northern China is more efficacious than monotherapy and is well tolerated. If MSDBP is > 90 mmHg after 4 weeks of treatment with 80 mg valsartan and 12.5 mg HCTZ the dose should be doubled to 160 mg valsartan and 25 mg HCTZ daily.
